Meeting
2019 Genitourinary Cancers Symposium
Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.
Authors
Juan Francisco Rodriguez-Moreno
HM Hospitales - Centro Integral Oncológico HM Clara Campal, Madrid, Spain
Juan Francisco Rodriguez-Moreno , Elena Sevillano , MD Fenor , Ricardo Collado Martín , Emilio Esteban , Ricardo Fernandez , Albert Font Pous , Pablo Gajate , José Muñoz-Langa , Sergio Vazquez-Estevez , Guillermo de Velasco , Juan Antonio Virizuela , Paloma Navarro , S Ruiz-LLorente , Luis Beltran , Cristina Rodríguez-Antona , Jesús GarcÃa-Donas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT03534492
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS503)
DOI
10.1200/JCO.2019.37.7_suppl.TPS503
Abstract #
TPS503
Poster Bd #
N13
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.
First Author: Juan Francisco Rodriguez-Moreno
Poster
2017 ASCO Annual Meeting
Phase II (window) preoperative study of olaparib with cisplatin or with durvalumab or alone or no treatment in patients with histologically proven head and neck squamous cell carcinoma who are candidates for surgery (OPHELIA).
First Author: Amanda Psyrri
Poster
2020 ASCO Virtual Scientific Program
Molecular correlates of response to preoperative olaparib alone or with cisplatin or with durvalumab in head and neck squamous cell carcinoma (HNSCC): A Hellenic Cooperative Oncology Group study.
First Author: Amanda Psyrri
Poster
2019 ASCO Annual Meeting
DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.
First Author: Enrique Grande